Greg Anderson studied Neuroscience at The University of Manchester; incorporating an industrial placement at Merck Sharp & Dohme’s Neuroscience Research Centre. He then remained in Manchester to complete a MRC-funded MRes. Greg later worked for GSK in their dedicated Phase I clinical trial unit in Sydney, Australia, before returning to the UK to work at GSK’s Psychiatry Centre of Excellence for Drug Discovery and its associated Genomics Core Facility.
Greg joined the IoPPN in 2008 with a MRC Case Award PhD Studentship in collaboration with TheraGenetics, focusing on pharmacogenomics of psychiatric treatments. This was followed by post-doctoral contracts working on the epigenetics of neural stem cell fate determination and genome editing as a tool for in vitro disease modelling.
Greg joined the Centre for Developmental Neurobiology in July 2015, where he helps support the technical needs of its members.
KCL PURE: https://kclpure.kcl.ac.uk/portal/greg.anderson.html
Research Gate: https://www.researchgate.net/profile/Greg_Anderson9